—A Webinar from Decision Resources
Based on our European Physician & Payer Forum report entitled Molecularly Driven Management and Maintenance Treatment of NSCLC: Physician and Payer Perspectives on the Changing Treatment Paradigms in Europe, Decision Resources is offering this exclusive webinar. Because this presentation will feature major findings, it is ONLY available to purchasers of this report.
Please contact us to learn how you can purchase this report and attend the webinar.
Treatment paradigms for non-small-cell lung cancer (NSCLC) in the EU5 (France, Germany, Italy, Spain and the United Kingdom) are undergoing significant changes as the molecular pathogenesis of the disease is further elucidated and researchers continue to make considerable advances in the use of novel therapeutic strategies. In particular, treatment of advanced disease is increasingly influenced by tumor molecular characteristics predictive of response to certain targeted agents. Retrospective and prospective analyses of clinical trial data on endothelial growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) led to the European approval in 2010 for AstraZeneca’s Iressa across all lines of therapy for mutant EGFR NSCLC, while Roche/OSI’s Tarceva was approved in August 2011 for first-line treatment of mutant EGFR NSCLC. Looking forward, clinical trials in patient populations enriched by inclusion of tumors with specific molecular characteristics will likely facilitate the approval of multiple new agents. An equally intriguing treatment strategy is maintenance therapy—a strategy that is now gaining traction in all markets. In an effort to delay disease progression and/or to extend survival in patients with advanced NSCLC, continuation or switch maintenance treatment may be prescribed.
Decision Resources surveyed 260 medical oncologists and interviewed 15 payers in the EU5 to assess their attitudes and expectations surrounding current and emerging therapies for molecular management and maintenance treatment of NSCLC and the evolving reimbursement environment these treatment strategies face.
This webinar, presented by Decision Resources Product Manager Janie Cox, Ph.D., will answer the following questions:
- How does the reimbursement and market access environment for key therapies used for NSCLC vary between EU5 countries? What cost control measures are employed to guide treatment, and how strictly is prescribing monitored by payers?
- To what extent do oncologists request testing for molecular characteristics and how will this evolve over the next two years?
- How does EGFR status influence first- and second-line treatment choices? What factors influence the choice between Iressa and Tarceva for mutated EGFR NSCLC? How will treatment of this disease subtype develop over the next two years?
- How do oncologists view key emerging therapies for the molecular management of NSCLC, such as Pfizer’s crizotinib, Boehringer Ingelheim’s Tomtovok, Pfizer’s dacomitinib, ArQule/Daiichi Sankyo/Kyowa Hakko Kirin’s tivantinib and Genentech/Roche/Chugai’s MetMAb?
- To what extent do advanced NSCLC patients receive maintenance treatment in 2011? How will this change over the next year? What factors contribute to an oncologist’s decision to prescribe or not to prescribe maintenance treatment? Do oncologists consider dual-maintenance therapy promising?
- How will the molecular management and maintenance treatment of NSCLC be affected by ongoing healthcare reforms and evolving cost-containment strategies in the EU5? How much of a market access lever is a predefined patient population? How much of a barrier is the cost of extended treatment with maintenance therapy? Do payers consider cost-sharing schemes to be a key market access tool?
Webinar Details Date & Time Presentation: 30 minutes Q & A: 15 minutes |
About the Speaker
|
Janie Cox, Ph.D., is the product manager of Decision Resources' European Physician & Payer Forum portfolio. Previously, Dr. Cox specialized in analysis of the non-small-cell lung cancer market. Prior to joining the company, she was a managing editor at Thomson Reuters, where her primary responsibility was providing information disclosed at major pharmaceutical conferences as content for Thomson Pharma and the IDdb. Dr. Cox holds a Ph.D. from the University of Bristol and a B.Sc. in immunology and microbiology from the University of Strathclyde, Glasgow. She has also worked as a postdoctoral scientist at the Institute for Animal Health.|
To learn how you can purchase this report and attend the webinar, please contact us using the information below. In North America In Europe In Japan |
Dr. Cox will conduct a live Q & A session after the presentation.
Physician and Payer Perspectives on Molecular Management and Maintenance Treatment of NSCLC: Maximizing Market Access Opportunities in the EU5
December 16 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).
Terms of Use | Privacy Policy | Contact Us | Careers
Decision Resources • 8 New England Executive Park • Burlington, MA 01803
You are receiving this email because you have previously requested information from Decision Resources. You can update your email preferences at any time.
© 2011 Decision Resources, LLC. All rights reserved.
